NYSE American - Delayed Quote USD

IGC Pharma, Inc. (IGC)

Compare
0.3450
+0.0137
+(4.12%)
At close: January 10 at 3:57:44 PM EST
0.3450
0.00
(0.00%)
After hours: 7:57:26 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
1,183.0000
1,345.0000
911.0000
397.0000
898.0000
Cost of Revenue
518.0000
612.0000
469.0000
203.0000
785.0000
Gross Profit
665.0000
733.0000
442.0000
194.0000
113.0000
Operating Expense
9,989.0000
10,531.0000
12,013.0000
15,622.0000
8,837.0000
Operating Income
-9,324.0000
-9,798.0000
-11,571.0000
-15,428.0000
-8,724.0000
Other Income Expense
-3,245.0000
-3,202.0000
65.0000
412.0000
-87.0000
Pretax Income
-12,569.0000
-13,000.0000
-11,506.0000
-15,016.0000
-8,811.0000
Net Income Common Stockholders
-12,569.0000
-13,000.0000
-11,506.0000
-15,016.0000
-8,811.0000
Diluted NI Available to Com Stockholders
-12,569.0000
-13,000.0000
-11,506.0000
-15,016.0000
-8,811.0000
Basic EPS
-0.20
-0.22
-0.22
-0.30
-0.21
Diluted EPS
-0.20
-0.22
-0.22
-0.30
-0.21
Basic Average Shares
69,201.4420
58,839.8680
52,576.2580
49,991.6310
41,963.3820
Diluted Average Shares
69,201.4420
58,839.8680
52,576.2580
49,991.6310
41,963.3820
Total Operating Income as Reported
-9,324.0000
-9,798.0000
-11,571.0000
-15,428.0000
-8,724.0000
Total Expenses
10,507.0000
11,143.0000
12,482.0000
15,825.0000
9,622.0000
Net Income from Continuing & Discontinued Operation
-12,569.0000
-13,000.0000
-11,506.0000
-15,016.0000
-8,811.0000
Normalized Income
-9,224.0000
-9,655.0000
-11,506.0000
-14,967.0000
-8,642.0000
EBIT
-9,324.0000
-9,798.0000
-11,571.0000
-15,428.0000
-8,724.0000
EBITDA
-8,693.0000
-9,161.0000
-10,914.0000
-14,777.0000
-8,246.0000
Reconciled Cost of Revenue
518.0000
612.0000
469.0000
203.0000
785.0000
Reconciled Depreciation
631.0000
637.0000
657.0000
651.0000
478.0000
Net Income from Continuing Operation Net Minority Interest
-12,569.0000
-13,000.0000
-11,506.0000
-15,016.0000
-8,811.0000
Total Unusual Items Excluding Goodwill
-3,345.0000
-3,345.0000
--
-49.0000
-169.0000
Total Unusual Items
-3,345.0000
-3,345.0000
--
-49.0000
-169.0000
Normalized EBITDA
-5,348.0000
-5,816.0000
-10,914.0000
-14,728.0000
-8,077.0000
3/31/2021 - 5/24/2006

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

OGEN Oragenics, Inc.
0.3430
+2.82%
 
APTO Aptose Biosciences Inc.
0.2200
+3.19%
 
INAB IN8bio, Inc.
0.3233
+3.42%
 
LYRA Lyra Therapeutics, Inc.
0.1955
-2.59%
 
CYCC Cyclacel Pharmaceuticals, Inc.
0.4199
+1.21%
 
VINC Vincerx Pharma, Inc.
0.1901
-1.50%
 
VTVT vTv Therapeutics Inc.
13.80
-2.06%
 
SPRB Spruce Biosciences, Inc.
0.3700
-2.63%
 
AIM AIM ImmunoTech Inc.
0.2150
-0.92%
 
VIRX Viracta Therapeutics, Inc.
0.1860
-0.91%